EDITORIAL ARTICLE
“To be or not to be” for PET in rheumatology. A marriage of love or of convenience?
Online publication date: 2017-03-22
Reumatologia 2017;55(1):9-11
REFERENCES (15)
1.
Matsui T, Nakata N, Nagai S, et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med 2009; 50: 920-926.
2.
Beckers C, Ribbens C, André B, et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med 2004; 45: 956-964.
3.
Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2958-2967.
4.
Yamashita H, Kubota K, Mimori A. Clinical value of whole-body PET/CT in patients with active rheumatic diseases 2014. Arthritis Res Ther 2014; 16: 423.
5.
Elzinga EH, van der Laken CJ, Comans EF, et al. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med 2011; 52: 77-80.
6.
Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010; 9: 195-199.
7.
O’Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85: 473-483.
8.
Sela O, Shoenfeld Y. Cancer in autoimmune diseases. Semin Arthritis Rheum 1988; 18: 77-87.
9.
Carter PH, Zhao Q. Clinically validated approaches to the treatment of autoimmune diseases. Expert Opin Investig Drugs 2010; 19: 195-213.
10.
Oh JR, Song HC, Kang SR, et al. The clinical usefulness of 18F-FDG PET/CT in patients with systemic autoimmune disease. Nucl Med Mol Imaging 2011; 45: 177-184.
11.
Ergül N, Çermik TF. FDG-PET or PET/CT in fever of unknown origin: the diagnostic role of underlying primary disease. Int J Mol Imaging 2011; 2011: 318051.
12.
Balink H, Bennink RJ, van Eck-Smit BL, Verberne HJ. The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria? Biomed Res Int 2014; 2014: 687608.
13.
Roivainen A, Parkkola R, Yli-Kerttula T, et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003; 48: 3077-3084.
14.
van der Laken CJ, Elzinga EH, Kropholler MA, et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)PK11195 and positron emission tomography. Arthritis Rheum 2008; 58: 3350-3355.
15.
Zeman MN, Scott PJ. Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging 2012; 2: 174-220.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
